Roslin Cells Retains ISO 9001 Certification
Roslin Cells retains certification to the internationally recognised quality management system standard, ISO 9001
Edinburgh, Scotland – 06 June 2011: Roslin Cells Ltd., world leaders in the isolation of new clinical grade undifferentiated stem cells, announced today that is has successfully retained certification to ISO 9001, the internationally recognised management system standard which serves as a benchmark for quality management systems.
In retaining certification, Roslin Cells has demonstrated a commitment to quality management and continuous improvement throughout all its business and operational activities. Having undergone an initial intensive fast-track assessment and certification in 2009 Roslin Cells has been inspected six times in two years by BSI Group, a leading global business services organisation providing standards-based solutions in more than 150 countries, and in that time has received no non-conformances.
A quote from the BSI assessment report reads: “This management system remains effective, dynamic and very comprehensive and is a good example of a graphic, explanatory and user friendly system giving the organisation their required consistency, ability to deliver objectives, and effective controls to deliver the product to the required standard within budget”.
“Our ongoing certification to ISO 9001 reflects the quality focussed mindset and commitment to quality which is evident in all our staff here at Roslin Cells. This certification is testament to the quality-focussed approach we maintain to all our activities from our administration all the way to our GMP-compliant manufacturing and how we build collaborations and partnerships.” said Kevin Bruce, Roslin Cells Quality Manager.
About Roslin Cells
Roslin Cells has already established itself as one of Europe’s leaders in the translation of stem cell research to clinical application and has already produced several GMP grade hESC lines which are being used in a pipeline of new cell therapies.
Roslin Cells Ltd was established as an independent company by Roslin Institute in 2006 with the aim of providing ethically sourced, pluripotent human cells manufactured to the highest quality available according to Good Manufacturing Practice (GMP standards). This level of quality is critical to their intended use in therapeutic applications. The Company now also assists academic and commercial researcher organisations to translate fundamental research into GMP compliant processes which can be used in the production of cell therapies. In October 2010 the Company announced its Cell Therapy Partner Program through which it helps the development of new cell therapies.
Roslin Cells is headquartered near Edinburgh, Scotland, and is a not for profit organisation.
For more information please contact;
Phone + 44 (0)131 478 2210; Email: media@roslincells.com
Monday, June 6, 2011 at 9:00AM 
